Replies to post #402003 on Anavex Life Sciences Corp (AVXL)

[McMagyar]

Thx mayo

[powerwalker]

Dr. Missling mentions brain atrophy - as we know, Lecanemab patients saw SIGNIFICANT brain atrophy, especially in the hippocampus. Looking forward to this data and hopefully some comparative charts.

Thanks, Jesse, for highlighting this aspect of the lec* ravaging drug. Another example of the fda's inability to focus on the details vs. laudatory praise/AA for a drug of insufficient benefits.

[Anshu2]

Haha. My takes from CM’s CC.

1. AD full data. In 2023? Not sure — could be 2024, 2025. But, I assure you asap.

2. Excellence trial endpoint. RIGHT NOW, our plan is delta-RSBQ, but you know us — can’t promise what it will be in 2 months, or when we see the data.

3. PDD OLD. Oops, are you guys still waiting for it?! Give us 6-12 more months. We need a few more months to compute an average of 400 values.

4. AD discussion with FDA. After we get our “hands” on full data (see #1 above), then we’ll talk **aggressively** with the agencies. Just 1-2 more years wait.

5. Other trials: All our previous trials have failed — so we are being extra cautious that these new ones succeed. So, that’s the reason for delay.

6. PDD trial full data: Forget about it!